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Impact of Cytochrome P450 2C19 Loss-of-Function
Polymorphism and of Major Demographic
Characteristics on Residual Platelet Function
After Loading and Maintenance Treatment With
Clopidogrel in Patients Undergoing Elective
Coronary Stent Placement
Willibald Hochholzer, MD,*‡ Dietmar Trenk, PHD,* Martin F. Fromm, MD,†
Christian M. Valina, MD,* Christian Stratz, MD,* Hans-Peter Bestehorn, MD,*
Heinz Joachim Büttner, MD,* Franz-Josef Neumann, MD*
Bad Krozingen and Erlangen, Germany; and Boston, Massachusetts
Objectives The aim of this study was to evaluate the relative impact of demographic and clinical variables versus the cyto-
chrome P450 2C19 (CYP2C19) polymorphism on antiplatelet effects of clopidogrel.
Background Platelet responses to clopidogrel show a marked interindividual variability with substantial impact on clinical
outcome. Several demographic and clinical characteristics as well as a polymorphism of CYP2C19 have been
described as predictors for a low response to clopidogrel.
Methods This analysis enrolled 760 patients undergoing elective coronary stent implantation after loading with 600 mg of
clopidogrel. Residual platelet aggregation was determined by optical aggregometry (adenosine diphosphate 5
mol/l) before discharge. We analyzed the predictive value of the CYP2C19*2 polymorphism and baseline vari-
ables for an insufficient antiplatelet response by multivariable regression analysis and classification and regres-
sion trees analysis and determined the proportion responsible for the antiplatelet response of these predictors
by multivariable linear regression analysis.
Results Major independent predictors for an insufficient antiplatelet response to clopidogrel were CYP2C19*2 carrier
status (odds ratio [OR]: 2.74; 95% confidence interval [CI]: 1.93 to 3.90) together with age (OR: 1.03; 95% CI:
1.01 to 1.05), diabetes mellitus (OR: 1.75; 95% CI: 1.19 to 2.56), and body mass index (OR: 1.06; 95% CI: 1.02
to 1.11). The classification and regression trees analysis demonstrated that CYP2C19*2 carrier status followed
by diabetes mellitus was the best discriminator between a sufficient and an insufficient antiplatelet response to
clopidogrel. The full linear regression model including all these parameters could only explain 11.5% of the anti-
platelet response (5.2% by CYP2C19*2 carrier status alone).
Conclusions Thus, our study does not suggest that, in patients critically dependent on adequate platelet inhibition, genotyp-
ing alone or in combination with clinical factors can replace phenotyping of platelet function. (Effect of Clopi-
dogrel Loading and Risk of PCI [EXCELSIOR]; NCT00457236). (J Am Coll Cardiol 2010;55:2427–34) © 2010
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.031v
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Bual antiplatelet therapy with aspirin and clopidogrel is the
stablished treatment for prevention of stent thrombosis
fter percutaneous coronary interventions (PCI) (1,2).
he efficacy of such treatment is hampered by the large
rom the *Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; †Institute of
xperimental and Clinical Pharmacology and Toxicology, University of Erlangen-
uremberg, Erlangen, Germany; and the ‡TIMI Study Group, Cardiovascular Division,
righam and Women’s Hospital, Department of Medicine, Harvard Medical School, 2ariability of platelet inhibition by clopidogrel (3). Sev-
ral independent clinical studies have demonstrated that
atients with high residual platelet reactivity on clopidogrel
ere at increased risk for stent thrombosis and other car-
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P450 2C19 Polymorphisms and Residual Platelet Activity June 1, 2010:2427–34diac complications (4–7). In the
EXCELSIOR (Impact of Extent
of Clopidogrel-Induced Platelet
Inhibition During Elective Stent
Implantation on Clinical Event
Rate) trial, patients with a high
on-clopidogrel residual platelet
aggregation (RPA) at day 1 after
PCI had a 3-fold increase in the
1-year incidence of death and
myocardial infarction (MI) after
elective stent placement as com-
pared with patients with an in-
termediate or low RPA (8). The
threshold for high on-clopidogrel
RPA identified by this study
was 14% after stimulation with
-mol/l adenosine diphosphate (ADP).
The variability of clopidogrel responses is a consequence of
ariable formation of the active metabolite (9,10). The highly
olymorphic cytochrome P450 (CYP) system of the liver plays
key role in this respect (11,12). Specifically, carriers of the *2
oss-of-function allele of CYP2C19 generate less amounts of
he active metabolite of clopidogrel, resulting in a decreased
ntiplatelet effect, and therefore carry an increased risk of major
dverse cardiac events after stent placement compared with
ild-type homozygotes of this gene (8,13–17).
After documentation of the impact of the variability of
he clopidogrel effect on clinical outcome, there has been
rowing interest in platelet function testing to guide anti-
latelet therapy (18). Alternatively, the development of
eans to predict responses to clopidogrel without perform-
ng platelet function assays is highly attractive. To this end,
esting for CYP polymorphisms, specifically CYP2C19*2,
as been suggested (17,19,20). Irrespective of genetic back-
round, however, there are a number of demographic and
linical variables that interfere with clopidogrel responses,
uch as age, body mass index (BMI), and diabetes
6,8,21,22). The relative role of these demographic and
linical variables versus the CYP2C19 polymorphism is
urrently unclear. Clarifying this issue is of major clinical
nterest, because it might help to guide the optimal choice of
est for assessing a patient’s risk of being a low responder to
lopidogrel and for tailoring antiplatelet therapy.
Therefore, we analyzed the EXCELSIOR dataset to
stimate the relative contribution of clinical variables gen-
rally on-hand and of carrier status for the CYP2C19*2 allele
or prediction of the antiplatelet effects of clopidogrel.
ethods
tudy population. Details of the EXCELSIOR study
esign have been published previously (6,8). Briefly, pa-
ients undergoing elective coronary stent placement after
retreatment with 600 mg of clopidogrel and aspirin (100
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
BMI  body mass index
CART  classification and
regression trees
CYP  cytochrome P450
DNA  deoxyribonucleic
acid
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RPA  residual platelet
aggregationg/day for at least 5 days) were eligible for this prospective aingle-center study conducted in a referral center setting in
ad Krozingen, Germany. We did not include patients with
cute MI according to the European Society of Cardiology/
merican College of Cardiology consensus document (23);
atients taking chronic oral anticoagulation or thienopyri-
ine treatment within the last 2 weeks before admission;
atients with contraindications to aspirin, clopidogrel, or
eparin; and patients with cancer or hemodialysis. The
tudy was approved by the ethics committee of the medical
aculty of the University of Freiburg, Germany. All patients
ave written informed consent.
tudy protocol. Before the intervention all patients re-
eived a loading dose of 600 mg of clopidogrel. Catheter-
zation was timed according to the routine schedule of the
atheterization laboratory. The PCI with stent placement
as performed as described previously (3,6). The choice of
tent type, bare-metal, paclitaxel-eluting, or sirolimus-
luting stent, was left to the operator’s discretion. All
atients received an intra-arterial dose of 100 to 140 U/kg
eparin; glycoprotein IIb/IIIa inhibitors were not allowed
xcept for bail-out. After PCI, all patients received aspirin
100 mg/day), lifelong, and clopidogrel (75 mg/day) for
0 days after placement of bare-metal stents or for 6 months
fter placement of at least 1 drug-eluting stent.
latelet function assay. As described previously (6,24),
latelet aggregation was assessed by turbidimetric aggre-
ometry with a 4-channel Bio/Data PAP4 aggregometer
Mölab, Langenfeld, Germany). Blood samples for platelet
unction testing were drawn before discharge at day 1 after
oading with clopidogrel, 2 to 4 h after intake of the first
aintenance dose (in the vast majority of patients between
6 and 24 h after loading dose). Samples were drawn into
ubes containing 3.8% sodium-citrate (Sarstedt, Nuem-
recht, Germany) and processed within 1 h after blood-
rawing. We prepared platelet-rich plasma by centrifuga-
ion of citrated venous blood at 750 g for 2 min and adjusted
o 275 to 325  109 thrombocytes/l by dilution with
latelet-poor plasma from the same patient. We used ADP
Sigma-Aldrich, Munich, Germany) to induce aggregation.
ight transmission in platelet-rich plasma was determined 5
in after addition of ADP at a final concentration of 5
mol/l. Results were expressed as percentage of maximal
ight transmission with platelet-poor plasma from the same
atient as reference (100% aggregation). The coefficient of
ariation of our optical aggregometry assay is 6.1% (3,6).
enotyping by TaqMan polymerase chain reaction. De-
ermination of genotype was performed as previously de-
cribed (8). In brief, genomic deoxyribonucleic acid (DNA)
as extracted from peripheral potassium ethylenediami-
etetraacetic acid-anticoagulated blood with the Flexigene
it (QIAGEN, Hilden, Germany) according to the man-
facturer’s instruction. After extraction, the concentration
f DNA was measured photometrically, and DNA was
iluted to a concentration of 5 mg/l. The CYP2C19*2
681GA; rs4244285) was genotyped with a commercially
vailable, validated Drug Metabolism Genotyping Assay
(
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ation (QPCR Master Mix, Abgene, Hamburg, Germany),
eaction mixtures were loaded in an ABI Prism Sequence
etector 7900 (Applied Biosystems). After polymerase
hain reaction, fluorescence yield for the 2 different dyes was
easured and presented in a 2-dimensional graph.
tatistical methods. The sample size calculation based on
he 30-day primary end point of EXCELSIOR was pub-
ished previously (6).
For all multivariable analyses, we chose the baseline
emographic and clinical variables assessed on admission to
ospital with a difference between the 2 strata defined by
re-discharge RPA (14% and 14%) at a p value 0.20
ith or without CYP2C19*2 carrier status (8). For identifi-
ation of possible predictors for a high on-clopidogrel RPA
RPA 14%) we used multivariable binary logistic regres-
ion models with RPA 14% as dependent variable. We
lso entered all identified variables in a classification and
egression trees (CART) analysis to determine the best
iscriminators for high on-clopidogrel RPA (chi-square
utomatic interaction detector algorithm, p value adjust-
ent by Bonferroni method). The percentage of variability
f on-clopidogrel RPA that could attribute to the variability
n independent variables was derived from partial 2 calcu-
ated by multivariable linear regression analysis with RPA as
ependent variable and entering dichotomous variables as
xed factors. To evaluate the improvement in our binary
odel by adding the CYP2C19*2 carrier status to the model,
ncluding only clinical variables, we calculated the net
eclassification improvement (based on the methods from
rank Harrell, run in R, Version 2.10.1, R Development
ore Team, Vienna, Austria). For all other statistical
nalyses, we used the SPSS software package, version 18
SPSS, Inc., Chicago, Illinois). In general, discrete variables
re reported as counts (percentages), and continuous vari-
bles are reported as mean  SD. For discrete variables, we
ested differences between groups with the chi-square test or
isher exact test when expected cell sizes were5. We used
he 2-tailed t test to compare continuous variables or the
ruskal-Wallis test for non-Gaussian variables. In the
-sided test, a p value 0.05 was regarded as significant.
esults
he entire cohort of the EXCELSIOR study comprised
02 patients, of which CYP2C19 genotype as well as
re-discharge RPA results were available from 760 patients.
table of baseline characteristics has previously been
ublished (8). The mean age in our population was 66 years,
he proportion of men was 72%, drug-eluting stents were
sed in 37% of patients, and no patient was treated with a
lycoprotein IIb/IIIa inhibitor.
ariability of on-clopidogrel RPA in strata defined by
YP2C19 genotype. In the entire cohort, the proportion of
atients with high on-clopidogrel RPA was 28.4%. Figure 1
hows a scatter plot of RPA in the 3 strata defined by IYP2C19 genotype: *2 homozygotes (n  15, 2%), *2
eterozygotes (n  218, 29%), and wild-type homozygotes
n  527, 69%). Although there was a highly significant
ifference in RPA, depending on CYP2C19 genotype, the
verlap was considerable. Accordingly, 22.4% of the wild-
ype homozygotes had to be classified as high on-
lopidogrel RPA, whereas 58.7% of the *2 heterozygotes
nd 53.3% of the *2 homozygotes did not meet the criteria
or high on-clopidogrel RPA. Thus, the sensitivity of
YP2C19*2 carrier status for detecting high on-clopidogrel
PA was only 45.1%, whereas the specificity was 75.0%.
ontribution of CYP2C19 genotype and clinical
haracteristics to on-clopidogrel RPA. The baseline
emographic characteristics of our study cohort have been
ublished (8). In univariable analyses, the clinical patient
haracteristics that showed the strongest association to high
n-clopidogrel RPA were age, BMI, and diabetes mellitus.
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Figure 1 CYP2C19 Genotype and RPA
(A) Scatter plot of residual platelet aggregation (RPA) in the 3 strata defined by
CYP2C19 genotype. Percentage indicates medians for genotype and red
dashed line displays threshold for high RPA (14%). The p value by Kruskal-
Wallis test between strata. (B) Box and whisker plots of RPA by genotype. The
boxes show medians and upper and lower quartiles of the data, whereas the
whiskers indicate the minimum and maximum values. ADP  adenosine
diphosphate; wt  wild-type.n addition, we found significant differences (p  0.05)
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P450 2C19 Polymorphisms and Residual Platelet Activity June 1, 2010:2427–34etween patients with high on-clopidogrel RPA and those
ith a low-to-intermediate on-clopidogrel RPA in arterial
ypertension, treatment with a nondihydropyridine calcium
ntagonist (verapamil or diltiazem), and previous balloon
ngioplasty. Further potentially relevant but nonsignificant
ifferences between the 2 strata (p  0.20) defined by high
n-clopidogrel RPA were found in platelet count as well as
ultivariate Binary Logistic Regression Analysisor Low Response to Clop dogrelTable 1 Multivariate Binary Logistic Regression Analysisfor Low Response to Clopidogrel
Odds Ratio
95% Confidence
Interval p Value
CYP2C19* polymorphism 2.738 1.925–3.895 0.001
Age (yrs) 1.031 1.010–1.052 0.003
Arterial hypertension 1.348 0.830–2.190 0.228
Diabetes mellitus 1.745 1.189–2.562 0.004
Body mass index (kg/m2) 1.061 1.016–1.109 0.008
Platelets ( 109/l) 0.997 0.994–1.000 0.059
ACE inhibitors 1.065 0.751–1.511 0.724
Nitrates 1.095 0.754–1.590 0.632
Verapamil/diltiazem 2.569 1.185–5.572 0.017
Previous balloon angioplasty 1.509 1.058–2.154 0.023
Previous CABG 1.282 0.783–2.101 0.323
Impaired LV function† 1.100 0.768–1.575 0.602
CCS angina class III or IV 0.667 0.443–1.003 0.052
esidual platelet aggregation 14%. *Cytochrome P450 2C19 681GA; †impaired left ventricu-
ar (LV) function (ejection fraction 55%).
ACE angiotensin converting enzyme; CABG coronary artery bypass grafting; CCS Canadian
ardiovascular Society.
Figure 2 CART Analysis for Low Response to Clopidogrel Includ
Correlation and regression trees (CART) analysis for low response to clopidogrel (residn treatment with angiotensin-converting enzyme inhibitor
nd nitrates, previous coronary artery bypass grafting, im-
aired left ventricular function (ejection fraction 55%),
nd Canadian Cardiovascular Society angina class III or IV.
hese variables were included in a multivariable binary
ogistic regression model for prediction of high on-
lopidogrel RPA. As shown in Table 1, this model con-
rmed that CYP2C19*2 carrier status was the strongest
redictor of high on-clopidogrel RPA. Also, age, diabetes
ellitus, and BMI prevailed as strong predictors in the
ultivariable analysis. Other clinical, procedural, and phar-
acotherapeutic characteristics with a significant associa-
ion with high on-clopidogrel RPA in the multivariable
odel were: treatment with a nondihydropyridine calcium
ntagonist (verapamil or diltiazem), and a previous balloon
ngioplasty. Addition of the clinical variables to a logistic
egression model that contained only CYP2C19*2 carrier
tatus as independent variable increased chi-square of model
rom 28.4 to 82.3.
From CART analysis, CYP2C19*2 carrier status again
merged as the strongest variable for classification (Fig. 2).
he second most relevant variable was diabetes mellitus,
ollowed by BMI. The frequency of high on-clopidogrel
PA in the classes derived from this CART model varied
rom 48% in CYP2C19*2 carriers with BMI 26 kg/m2 to
6% in nondiabetic CYP2C19 wild-type homozygotes with
BMI 30 kg/m2.
he CYP2C19 681G>A Polymorphism
telet aggregation [RPA] 14%) including the CYP2C19 681GA polymorphism.ing t
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June 1, 2010:2427–34 P450 2C19 Polymorphisms and Residual Platelet ActivityWe also analyzed on-clopidogrel RPA as a continuous
ariable and estimated the individual contribution of the
ame variables as in the logistic model to the variation
f on-clopidogrel RPA in a linear regression model. A linear
egression model that only comprises CYP2C19*2 carrier
tatus could explain 4.6% of the variability in on-clopidogrel
PA, whereas the full model comprising CYP2C19*2 carrier
tatus and the clinical variables could explain 11.5%. In the
ull model (Table 2), we found that 5.2% of the observed
ariability in RPA could be attributed to CYP2C19*2 carrier
tatus (p  0.001), 1.0% to age (p  0.006), 1.0% to BMI
p 0.008), and 1.2% to the presence or absence of diabetes
p  0.003).
lassification of the probability of high on-clopidogrel
PA based on clinical characteristics alone. Figure 3
llustrates the interaction of age, BMI, and diabetes in their
ultivariable Linear Regression Modelor RPA After Stimulation With 5 mol/l ADPTable 2 Multivariable Linear Regression Modelfor RPA After Stimulation With 5 mol/l ADP
Partial 2 p Value
CYP2C19* polymorphism 0.052 0.001
Age (yrs) 0.010 0.006
Arterial hypertension 0.001 0.386
Diabetes mellitus 0.012 0.003
Body mass index (kg/m2) 0.010 0.008
Platelets ( 109/l) 0.010 0.006
ACE inhibitors 0.001 0.403
Nitrates 0.001 0.890
Verapamil/diltiazem 0.010 0.006
Previous balloon angioplasty 0.007 0.026
Previous CABG 0.001 0.435
Impaired LV function† 0.001 0.945
CCS angina class III or IV 0.004 0.081
Cytochrome P450 2C19 681GA; †impaired LV function (ejection fraction 55%).
ADP  adenosine diphosphate; RPA  residual platelet aggregation; other abbreviations as in
able 1.
Figure 3 Proportion of Patients With Low Response to Clopidog
Proportion of patients with low response to clopidogrel (residual platelet aggregatimpact on the percentage of patients with high on-
lopidogrel RPA. In nondiabetic subjects, the increase in
he proportion of patients with high on-clopidogrel RPA
ith age and BMI was conspicuous, ranging from 9% in
ean (BMI 25 kg/m2), young (age 60 years) patients to
0% in obese (BMI 30 kg/m2), elderly (age 70 years)
atients. By contrast, diabetic patients, in general, com-
rised more patients with high on-clopidogrel RPA than
ondiabetic patients, but the effect of age and BMI was less
rominent. With a chi-square of 50.7, a logistic regression
odel that included only clinical variables was less predic-
ive than the full model comprising also CYP2C19*2 carrier
tatus (see the preceding text). The addition of the CYP2C19*2
arrier status significantly improved both reclassification
net reclassification improvement  0.403, p  0.001) and
he discrimination as calculated by the integrated discrimi-
ation improvement (p  0.001).
When CYP2C19*2 carrier status was not entered (Fig. 4),
he CART model identified diabetes mellitus, age, and
ypertension as variables with statistically significant rele-
ance to classification. The frequency of high on-
lopidogrel RPA varied from 38% in diabetic patients to
6% in nondiabetic patients without hypertension.
In the multivariable linear regression model, the clinical
ariables without CYP2C19*2 carrier status could explain
.7% of the variability in on-clopidogrel RPA.
iscussion
enetic impact on platelet function. The central message
f our analysis of the interaction of genomic and clinical
actors with on-clopidogrel platelet function in a large
ohort of patients undergoing elective PCI is that the
YP2C19*2 loss-of-function polymorphism and several
linical variables show a statistical highly significant associ-
tion with high on-clopidogrel RPA. Nevertheless, these
ccording to Age, Body Mass Index, and Diabetes Mellitus
A] 14%) according to age, body mass index, and diabetes mellitus.rel A
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P450 2C19 Polymorphisms and Residual Platelet Activity June 1, 2010:2427–34ariables do not suffice to predict high on-clopidogrel RPA
ith the precision needed for clinical decision-making. This
essage is based on 4 key observations: 1) the CYP2C19*2
oss-of-function polymorphism was the strongest predictor
f high on-clopidogrel RPA; 2) diabetes mellitus, age, and
MI were the clinical patient characteristics most strongly
ssociated with high on-clopidogrel RPA; 3) a CYP2C19*2
arrier status together with all demographic and clinical
redictors for high on-clopidogrel could only explain 11.5%
f residual platelet reactivity; and 4) the CART derived
rom these variables did not identify any subgroup in which
ore than 48% or 16% of the patients showed high
n-clopidogrel RPA.
Despite a statistically robust association of CYP2C19*2
arrier status with high on-clopidogrel RPA, CYP2C19*2
arrier status accounted for only 4.6% of the variability in
n-clopidogrel RPA. A possible explanation for this finding
ight be that other genomic conditions could play a role as
ell. However, other CYP polymorphisms that several
roups including ourselves previously investigated either
ad little impact on platelet function during clopidogrel
reatment or were too rare to play a role in the given sample
ize (14,15,25,26). Likewise, we and others did not detect a
elevant contribution of known polymorphisms of genes
ncoding for transporter proteins high on-clopidogrel RPA
26–28), although 1 study reported an association of
BCB1 polymorphism with clinical outcome in patients
Figure 4 CART Analysis for Low Response to Clopidogrel Exclu
Correlation and regression trees (CART) analysis for low response to clopidogrel (residaking clopidogrel (29). Thus, according to the current bnowledge, we were able to include the most relevant
enetic polymorphism. Apart from genetic background,
linical conditions and concomitant drug therapy might
nterfere with on-clopidogrel RPA. We found that consid-
ration of the clinical conditions in conjunction with
YP2C19*2 carrier status improved the prediction of high
n-clopidogrel RPA, and 11.5% of the variability in on-
lopidogrel RPA could be explained by a combination of
linical variables and CYP2C19*2 carrier status. The stron-
est clinical patient characteristics to predict high on-
lopidogrel RPA were diabetes mellitus, age, and BMI.
onsidered together, these clinical factors are more relevant
or prediction of high on-clopidogrel RPA than CYP2C19*2
arrier status alone, and addition of CYP2C19*2 carrier
tatus to these factors could not improve the prediction
ubstantially.
mpact of medication and patient characteristics on
latelet function. Our findings on diabetes mellitus, age,
nd BMI are consistent with some but not all clinical studies
hat investigated factors affecting response to clopidogrel
ithout assessment of the genetic background (21,30,31).
iabetes has also been associated in 2 other studies with low
esponse to clopidogrel in patients after coronary interven-
ion (21,30). The impact of age on the response to many
rugs is well-known (32). Surprisingly, little is known
egarding the interaction of age with clopidogrel response.
nly 1 trial has identified an age above 65 years as a possible
the CYP2C19 681G>A Polymorphism
telet aggregation [RPA] 14%) excluding the CYP2C19 681GA polymorphism.ding
ual plaut not strong predictor for a low antiplatelet response (21).
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June 1, 2010:2427–34 P450 2C19 Polymorphisms and Residual Platelet Activityata regarding BMI, so far, were inconsistent, because only
analysis could detect an impact of the BMI on the effect
f clopidogrel (31). Another multivariable analysis did not
onfirm BMI as predictive for an insufficient response to
lopidogrel (21).
There are 2 previous studies that investigated the rele-
ance of genetic and nongenetic factors for clopidogrel
esponses (33,34). Aleil et al. (33) identified body weight
nd CYP2C19*2 carrier status but not diabetes mellitus as
ndependent predictors for a low response to clopidogrel and
howed that an increase in maintenance dose can overcome
his effect. In the analysis of Geisler et al. (34), nongenetic
actors were less-relevant compared with our current study,
ut age and diabetes mellitus were also identified as signif-
cant predictors of clopidogrel response. We attribute the
iscrepancies with our results to substantially smaller sample
izes (n  153 and n  237, respectively) and the inclusion
f both stable and unstable patients in the second study.
We identified, apart from the patient characteristics to
redict high on-clopidogrel RPA, interaction of nondihy-
ropyridine calcium antagonists (verapamil and diltiazem)
ith the effect of clopidogrel—most likely due to common
etabolism via hepatic cytochromes. Our findings are
artially in line with a recent study (35). In this study,
owever, nearly all patients were treated with dihydropyri-
ine calcium-channel blockers, whereas in our dataset this
ype of calcium antagonist had no significant effect on
lopidogrel response. Because only a minority of our pa-
ients (4.1%) received nondihydropyridine calcium-channel
lockers, the relevance of this treatment to the overall
n-clopidogrel RPA was limited. Nevertheless, our data
uggest avoiding nondihydropyridine calcium-channel
lockers in patients needing treatment with clopidogrel.
tudy limitations. Our findings can only explain a small
art of the observed variability in on-clopidogrel RPA. This
eans that there are still some relevant factors interfering
ith clopidogrel responses that are yet unknown. These
ight include novel gene polymorphisms that, so far, have
ot been identified or investigated as well as clinical and
emographic factors or noncompliance, which were not
onsidered. We cannot exclude that the prediction of
lopidogrel responses might become better as further factors
merge.
All patients in our cohort receiving a proton pump
nhibitor (8%) were treated with pantoprazole, which has
ot been associated with increased platelet reactivity in
atients treated with clopidogrel—in contrast to omeprazole
r esomeprazole (36). Therefore, our analysis could not
valuate the impact of this drug class.
We also need to consider that some of the observed
ariability was introduced by variations in sampling condi-
ions, timing of the clopidogrel maintenance dose, and
catter of the platelet assay. To minimize these confounders
e implemented a strict protocol for drug intake and blood
ampling. In addition, we could verify a low coefficient of
ariation (6%) for our optical aggregometry method. Ourndings only apply to stable patients undergoing elective
CI. We purposely excluded the influence of overt heart
ailure and MI, which have been shown to modify the acute
esponses to clopidogrel substantially.
linical implications. Given the risks associated with poor
uppression of platelet function, identification of patients
ith high on-clopidogrel platelet reactivity is of major
linical interest. In these patients, alternative, more potent
ntiplatelet regimens have to be instituted or they might be
neligible for high-risk interventions such as the placement
f multiple stents or left main interventions. Nevertheless,
latelet function assays have not entered routine clinical
ractice in most centers, because they are technically de-
anding, poorly standardized, or expensive. Large-scale
tudies assessing easy-to-use point-of-care assays are under
ay. Until these assays have found their way into clinical
ractice, clinical or laboratory predictors of a low response to
lopidogrel are highly desirable.
A potentially attractive candidate in this respect is the
YP2C19*2 polymorphism (8,13,14). Independent of clo-
idogrel intake, determination of this genetic trait might
ive an estimate of the probability of a low response to
lopidogrel. Our current data, despite confirming the strong
mpact of the CYP2C19 loss-of-function polymorphism on
ntiplatelet effect of clopidogrel, suggest that genotyping for
YP2C19 is insufficient for clinical decision-making with-
ut platelet function testing. Addition of clinical variables
ould not fully correct this shortcoming.
Thus, our study does not suggest that, in patients
ritically dependent on adequate platelet inhibition, geno-
yping alone or in combination with clinical factors can
eplace phenotyping of platelet function.
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